CBT vs. CPRX
Compare and contrast key facts about Cabot Corporation (CBT) and Catalyst Pharmaceuticals, Inc. (CPRX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CBT or CPRX.
Correlation
The correlation between CBT and CPRX is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
CBT vs. CPRX - Performance Comparison
Key characteristics
CBT:
-0.77
CPRX:
1.20
CBT:
-1.06
CPRX:
2.13
CBT:
0.88
CPRX:
1.24
CBT:
-0.68
CPRX:
1.81
CBT:
-1.44
CPRX:
7.42
CBT:
17.77%
CPRX:
7.32%
CBT:
34.01%
CPRX:
41.75%
CBT:
-82.87%
CPRX:
-94.25%
CBT:
-36.21%
CPRX:
-9.21%
Fundamentals
CBT:
$4.20B
CPRX:
$3.03B
CBT:
$7.51
CPRX:
$1.31
CBT:
10.32
CPRX:
18.55
CBT:
1.83
CPRX:
0.00
CBT:
1.06
CPRX:
6.16
CBT:
3.10
CPRX:
4.16
CBT:
$3.91B
CPRX:
$534.65M
CBT:
$973.00M
CPRX:
$451.07M
CBT:
$600.00M
CPRX:
$177.46M
Returns By Period
In the year-to-date period, CBT achieves a -18.58% return, which is significantly lower than CPRX's 11.98% return. Over the past 10 years, CBT has underperformed CPRX with an annualized return of 8.34%, while CPRX has yielded a comparatively higher 21.42% annualized return.
CBT
-18.58%
-8.55%
-35.09%
-26.09%
20.69%
8.34%
CPRX
11.98%
2.77%
-2.34%
49.33%
37.00%
21.42%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CBT vs. CPRX — Risk-Adjusted Performance Rank
CBT
CPRX
CBT vs. CPRX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Cabot Corporation (CBT) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
CBT vs. CPRX - Dividend Comparison
CBT's dividend yield for the trailing twelve months is around 2.33%, while CPRX has not paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CBT Cabot Corporation | 2.33% | 1.85% | 1.88% | 2.21% | 2.53% | 3.12% | 2.90% | 3.04% | 2.02% | 2.22% | 2.68% | 1.96% |
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
CBT vs. CPRX - Drawdown Comparison
The maximum CBT drawdown since its inception was -82.87%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for CBT and CPRX. For additional features, visit the drawdowns tool.
Volatility
CBT vs. CPRX - Volatility Comparison
The current volatility for Cabot Corporation (CBT) is 9.77%, while Catalyst Pharmaceuticals, Inc. (CPRX) has a volatility of 13.05%. This indicates that CBT experiences smaller price fluctuations and is considered to be less risky than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
CBT vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Cabot Corporation and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CBT vs. CPRX - Profitability Comparison
CBT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Cabot Corporation reported a gross profit of 241.00M and revenue of 936.00M. Therefore, the gross margin over that period was 25.8%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a gross profit of 123.51M and revenue of 141.42M. Therefore, the gross margin over that period was 87.3%.
CBT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Cabot Corporation reported an operating income of 162.00M and revenue of 936.00M, resulting in an operating margin of 17.3%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported an operating income of 63.37M and revenue of 141.42M, resulting in an operating margin of 44.8%.
CBT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Cabot Corporation reported a net income of 94.00M and revenue of 936.00M, resulting in a net margin of 10.0%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a net income of 56.74M and revenue of 141.42M, resulting in a net margin of 40.1%.